205 related articles for article (PubMed ID: 30262206)
1. Is hypertriglyceridemia atherogenic?
Roubille F; Sultan A; Huet F; Leclercq F; Macia JC; Gervasoni R; Delseny D; Akodad M; Roubille C
Presse Med; 2018 Sep; 47(9):757-763. PubMed ID: 30262206
[TBL] [Abstract][Full Text] [Related]
2. Hypertriglyceridemia and cardiovascular risk reduction.
Jacobson TA; Miller M; Schaefer EJ
Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
[TBL] [Abstract][Full Text] [Related]
3. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease.
Brinton EA
Cardiol Clin; 2015 May; 33(2):309-23. PubMed ID: 25939302
[TBL] [Abstract][Full Text] [Related]
4. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.
Toth PP
Vasc Health Risk Manag; 2016; 12():171-83. PubMed ID: 27226718
[TBL] [Abstract][Full Text] [Related]
5. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
Fan W; Philip S; Granowitz C; Toth PP; Wong ND
Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
[TBL] [Abstract][Full Text] [Related]
6. Hypertriglyceridemia: the importance of identifying patients at risk.
Kushner PA; Cobble ME
Postgrad Med; 2016 Nov; 128(8):848-858. PubMed ID: 27710158
[TBL] [Abstract][Full Text] [Related]
7. Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review.
Sascău R; Clement A; Radu R; Prisacariu C; Stătescu C
Nutrients; 2021 May; 13(6):. PubMed ID: 34067469
[TBL] [Abstract][Full Text] [Related]
8. Is hypertriglyceridemia atherogenic?
Huet F; Roubille C; Roubille F
Curr Opin Lipidol; 2019 Aug; 30(4):291-299. PubMed ID: 31145120
[TBL] [Abstract][Full Text] [Related]
9. Lipid disorders in type 2 diabetes.
Laakso M
Endocrinol Nutr; 2009 Dec; 56 Suppl 4():43-5. PubMed ID: 20629231
[No Abstract] [Full Text] [Related]
10. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
Nordestgaard BG
Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
12. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.
Standl E
Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811
[TBL] [Abstract][Full Text] [Related]
13. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.
Tenenbaum A; Klempfner R; Fisman EZ
Cardiovasc Diabetol; 2014 Dec; 13():159. PubMed ID: 25471221
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
[TBL] [Abstract][Full Text] [Related]
16. [Statin therapy for atherogenic hypertriglyceridemia].
Koba S
Nihon Rinsho; 2013 Sep; 71(9):1655-60. PubMed ID: 24205730
[TBL] [Abstract][Full Text] [Related]
17. Drugs for hypertriglyceridemia.
Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
[No Abstract] [Full Text] [Related]
18. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
19. Role of fibrates in the management of hypertriglyceridemia.
Rader DJ; Haffner SM
Am J Cardiol; 1999 May; 83(9B):30F-35F. PubMed ID: 10357573
[TBL] [Abstract][Full Text] [Related]
20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
